Inhibition of indoleamine 2,3-dioxygenase promotes vascular inflammation and increases atherosclerosis in Apoe-/- mice

Cardiovascular Research

Volumn 106, Issue 2, 2015, Pages 295-302

  Polyzos, Konstantinos A ^a   Ovchinnikova, Olga ^a   Berg, Martin ^a   Baumgartner, Roland ^a   Agardh, Hanna ^a   Pirault, John ^a   Gisterå, Anton ^a   Assinger, Alice ^b   Laguna Fernandez, Andres ^a   Bäck, Magnus ^a   Hansson, Göran K ^a   Ketelhuth, Daniel F J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

3 Hydroxyanthranilic acid (3 HAA); Atherosclerosis; Indoleamine 2,3 dioxygenase (IDO); Inflammation; Kynurenine

Indexed keywords

1 METHYL TRYPTOPHAN; 3 HYDROXYANTHRANILATE 3,4 DIOXYGENASE; 3 HYDROXYANTHRANILIC ACID; APOPROTEIN; CHLORDANE; CHOLESTEROL; COLLAGEN; DRINKING WATER; GAMMA INTERFERON; HEME OXYGENASE 1; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; KYNURENINASE; LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; SMOOTH MUSCLE ACTIN; TRIACYLGLYCEROL; TRYPTOPHAN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; APOLIPOPROTEIN E; KYNURENINE; TRYPTOPHAN METHYL ESTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ARCH; AORTA ROOT; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIOACCUMULATION; CASE REPORT; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; IMMUNOHISTOLOGY; IMMUNOREGULATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; SMOOTH MUSCLE FIBER; TUNICA MEDIA; UPREGULATION; VASCULITIS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATION; KYNURENINE; MICE, KNOCKOUT; TRYPTOPHAN; TUNICA MEDIA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84929070239     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvv100     Document Type: Article

References (35)

1. WHO. Global Status Report on Noncommunicable Diseases 2010. Geneva: World Health Organization; 2011.
2. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007;116: 1832-1844.
3. Mellor AL, Munn DH. Tryptophan catabolism and regulation of adaptive immunity. J Immunol 2003;170:5809-5813.
4. Sakash JB, Byrne GI, Lichtman A, Libby P. Cytokines induce indoleamine 2, 3-dioxygenase expression in human atheroma-asociated cells: implications for persistent Chlamydo-phila pneumoniae infection. Infect Immun 2002;70:3959-3961.
5. Munn DH, Mellor AL. Indoleamine 2, 3 dioxygenase and metabolic control of immune responses. Trends Immunol 2013;34:137-143.
6. Hansson GK, Hellstrand M, Rymo L, Rubbia L, Gabbiani G. Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells. J Exp Med 1989;170:1595-1608.
7. Sakurai K, Zou JP, Tschetter JR, Ward JM, Shearer GM. Effect of indoleamine 2, 3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002;129:186-196.
8. Szanto S, Koreny T, Mikecz K, Glant TT, Szekanecz Z, Varga J. Inhibition of indoleamine 2, 3-dioxygenase-mediated tryptophan catabolism accelerates collagen-inducedarthritis in mice. Arthritis Res Ther 2007;9:R50.
9. Taher YA, Piavaux BJ, Gras R, van Esch BC, Hofman GA, Bloksma N, Henricks PA, van Oosterhout AJ. Indoleamine 2, 3-dioxygenase-dependent tryptophan metabolites con-tributetotolerance induction during allergen immunotherapyinamouse model. JAllergy Clin Immunol 2008;121:983-991 e2.
10. Gurtner GJ, Newberry RD, Schloemann SR, McDonald KG, Stenson WF. Inhibition of indoleamine 2, 3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology 2003;125:1762-1773.
11. Pedersen ER, Svingen GF, Schartum-Hansen H, Ueland PM, Ebbing M, Nordrehaug JE, Igland J, Seifert R, Nilsen RM, Nygard O. Urinary excretion of kynurenine and trypto-phan, cardiovascular events, and mortality after elective coronary angiography. Eur Heart J 2013;34:2689-2696.
12. Zhang L, Ovchinnikova O, Jonsson A, Lundberg AM, Berg M, Hansson GK, Ketelhuth DF. The tryptophan metabolite 3-hydroxyanthranilic acid lowers plasma lipids and decreases atherosclerosis in hypercholesterolaemic mice. Eur Heart J 2012;33: 2025-2034.
13. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH. Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007;67:792-801.
14. Ravishankar B, Liu H, Shinde R, Chandler P, Baban B, Tanaka M, Munn DH, Mellor AL, Karlsson MC, McGaha TL. Tolerance to apoptotic cells is regulated by indoleamine 2, 3-dioxygenase. Proc Natl Acad Sci USA 2012;109:3909-3914.
15. Hermansson A, Ketelhuth DF, Strodthoff D, Wurm M, Hansson EM, Nicoletti A, Paulsson-Berne G, Hansson GK. Inhibition of T cell response to native low-density lipo-protein reduces atherosclerosis. J Exp Med 2010;207:1081-1093.
16. Badawy AA, Morgan CJ. Rapid isocratic liquid chromatographic separation and quantification of tryptophan and six kynurenine metabolites in biological samples with ultraviolet and fluorimetric detection. Int J Tryptophan Res 2010;3:175-186.
17. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2, 3-dioxygenase, and tryptophan catabolism. FASEB J 1991;5:2516-2522.
18. Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, Ling L. Kynurenic acidasa ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 2006;281: 22021-22028.
19. Tiszlavicz Z, Nemeth B, Fulop F, Vecsei L, Tapai K, Ocsovszky I, Mandi Y. Different inhibitory effects of kynurenic acid and a novel kynurenic acid analogue on tumour necrosis factor-alpha (TNF-alpha) production by mononuclear cells, HMGB1 production by monocytes and HNP1-3 secretion by neutrophils. Naunyn Schmiedebergs Arch Pharmacol 2011;383:447-455.
20. Krause D, Suh HS, Tarassishin L, Cui QL, Durafourt BA, Choi N, Bauman A, Cosenza-Nashat M, Antel JP, Zhao ML, Lee SC. The tryptophan metabolite 3-hydroxyanthranilic acid plays anti-inflammatory and neuroprotective roles during inflammation: role of hemeoxygenase-1. Am J Pathol 2011;179:1360-1372.
21. Pae HO, Oh GS, Lee BS, Rim JS, Kim YM, Chung HT. 3-Hydroxyanthranilic acid, one of L-tryptophan metabolites, inhibits monocyte chemoattractant protein-1 secretion and vascular cell adhesion molecule-1 expression via heme oxygenase-1 induction in human umbilical vein endothelial cells. Atherosclerosis 2006;187:274-284.
22. Cuffy MC, Silverio AM, Qin L, Wang Y, Eid R, Brandacher G, Lakkis FG, Fuchs D, Pober JS, Tellides G. Induction of indoleamine 2, 3-dioxygenase in vascular smooth muscle cells by interferon-gamma contributes to medial immunoprivilege. J Immunol 2007;179: 5246-5254.
23. Weck KE, Dal Canto AJ, Gould JD, O'Guin AK, Roth KA, Saffitz JE, Speck SH, Virgin HW. Murine gamma-herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-gamma responsiveness: a new model for virus-induced vascular disease. Nat Med 1997;3:1346-1353.
24. Dal Canto AJ, Swanson PE, O'Guin AK, Speck SH, Virgin HW. IFN-gamma action in the media of the great elastic arteries, a novel immunoprivileged site. J Clin Invest 2001;107: R15-R22.
25. Moreno PR, Purushothaman KR, Fuster V, O'Connor WN. Intimomedial interface damage and adventitial inflammation is increased beneath disrupted atherosclerosis in the aorta: implications for plaque vulnerability. Circulation 2002;105:2504-2511.
26. Crawford T, Levene CI. Medial thinning in atheroma. J Pathol Bacteriol 1953;66:19-23.
27. Kasper HU, Schmidt A, Roessner A. Expression of the adhesion molecules ICAM, VCAM, and ELAM in the arteriosclerotic plaque. Gen Diagn Pathol 1996;141:289-294.
28. Chang MY, Smith C, DuHadaway JB, Pyle JR, Boulden J, Soler AP, Muller AJ, Laury-Kleintop LD, Prendergast GC. Cardiac and gastrointestinal liabilities causedbyde-ficiency in the immune modulatory enzyme indoleamine 2, 3-dioxygenase. Cancer Biol Ther 2011;12:1050-1058.
29. Terness P, Bauer TM, Rose L, Dufter C, Watzlik A, Simon H, Opelz G. Inhibition of allo-geneic T cell proliferation by indoleamine 2, 3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 2002;196:447-457.
30. Qian F, Villella J, Wallace PK, Mhawech-Fauceglia P, Tario JD Jr, Andrews C, Matsuzaki J, Valmori D, Ayyoub M, Frederick PJ, Beck A, Liao J, Cheney R, Moysich K, Lele S, Shrikant P, Old LJ, Odunsi K. Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan inreversing indoleamine-2, 3-dioxygenase-mediated arrestofT-cell proliferation in human epithelial ovarian cancer. Cancer Res 2009;69:5498-5504.
31. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2is the preferred biochemical target of the antitumor indoleamine 2, 3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 2007;67:7082-7087.
32. Meininger D, Zalameda L, Liu Y, Stepan LP, Borges L, McCarter JD, Sutherland CL. Purification and kinetic characterization of human indoleamine 2, 3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors. Biochim Biophys Acta 2011;1814:1947-1954.
33. Belladonna ML, Grohmann U, Guidetti P, Volpi C, Bianchi R, Fioretti MC, Schwarcz R, Fallarino F, Puccetti P. Kynurenine pathway enzymes in dendritic cells initiate tolerogen-esis in the absence of functional IDO. J Immunol 2006;177:130-137.
34. Takamatsu M, Hirata A, Ohtaki H, Hoshi M, Hatano Y, Tomita H, Kuno T, Saito K, Hara A. IDO1 playsanimmunosuppressive rolein2, 4, 6-trinitrobenzene sulfate-induced colitis in mice. J Immunol 2013;191:3057-3064.
35. Rytelewski M, Meilleur CE, Yekta MA, Szabo PA, Garg N, Schell TD, Jevnikar AM, Sharif S, Singh B, Haeryfar SM. Suppressionof immunodominant antitumor and antiviral CD8+ T cell responses by indoleamine 2, 3-dioxygenase. PLoS ONE 2014;9:e90439.